Loading your page…
Each register with its number of medicines and a few of them.
SFDA · 2 medicines · Historical list
FDA · 2 medicines
Anvisa · 1 medicine · Historical list
Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.
Health Canada · 1 medicine · Historical list
TFDA · 1 medicine · Historical list
Every register, a page at a time. Strengths and packs are on each medicine’s page.
4 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Gemifloxacin Mesylate | United States | 320MG BASE | tablet | Not marketed | Orbion Pharms |
| Factive | United States | 320MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet | Not marketed | LG Chem LTD |
| Gatifloxacin | United States | 0.3%, 0.5% | solution/drops | Marketed | Caplin |
| Gatifloxacin | United States | 0.3% | solution | Tentative approval | Hi-Tech Pharmacal |
The same brand on several registers.
The companies holding its medicines, the most first.
How the registers write it, in their own languages.
Compiled by Prognia from the public medicine registers of Anvisa, FDA, Health Canada, SFDA and TFDA. Each medicine’s page names its own source, licence and attribution.
Report an error or request removalCorrections from a register or a company are welcome.
For reference and learning, not treatment advice. Always check the official product information.
